Drug Profile
Research programme: radiation protection therapeutics - Quigley Pharma
Alternative Names: QR-335; QR-336Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Quigley Pharma
- Class Phytostanols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Radiation injuries
- Discontinued Radiation-induced skin damage
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Radiation-injuries in USA
- 31 Oct 2006 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
- 03 Oct 2006 Preclinical data from a media release have been added to the Cancer pharmacodynamics section